Abstract:BackgroundNitrous oxide (N 2 O), used medically for its analgesic and anxiolytic properties, has emerged as a common recreational substance, leading to a rise in chronic toxicity cases. N 2 O abuse induces peripheral neurological damage with a spectrum of clinical presentations, ranging from mild sensory disturbances to severe motor deficits. Neurological complications from N 2 O include axonal and demyelinating neuropathies, leading to diagnostic and prognostic challenges. The pathophysiology of N 2 O toxicity is linked to functional inactivation of vitamin B12, resulting in biochemical and electrophysiological alterations. This study aims to enhance understanding of N 2 O pathophysiology by examining metabolic changes in consumers with axonal and demyelinating patterns.MethodsThis study included 35 patients with recent N 2 O abuse (last declarative consumption within the past week) who were treated at Lille University Hospital between March 2020 and April 2023 and underwent electromyography. The collected clinical features encompassed sensory symptoms, motor weakness, gait abnormalities and deep tendon reflexes. Patients were classified based on clinical phenotypes, distinguishing between length-dependent and non-length dependent, sensory or sensory-motor involvement and their peripheral neuropathy disability (PND) score (ranging from I to IV). Neurophysiological data analysis followed the criteria of Hadden et al. to identify patients with demyelinating criteria, while those lacking demyelinating criteria were categorized as "axonal" in the neuropathy group. Simultaneously, biochemical evaluations of serum vitamin B12 and B9 by CLIA methods (Roche), along with plasma homocysteine by LC/MS/MS and CLIA methods (Snibe), methylmalonic acid (MMA), and methionine by LC/MS/MS, were systematically performed for all patients.Results40% of the selected patients exhibited demyelination criteria. The demyelinated group showed a significantly higher disability PND score compared to the axonal group (3.0 and 2.2, respectively; p-value = 0.028). Elevated levels of homocysteine and methylmalonic acid were found in all patients. Interestingly, plasma concentrations of homocysteine were significantly higher in the group of patient with axonal outcomes compared to the demyelinating group (90 μM and 114 μM; p-value = 0.04), suggesting an involvement of homocysteine in the type of lesion related to N 2 O abuse.ConclusionsThis study highlights the diverse electrophysiological manifestations of N 2 O-induced neuropathy and highlight the potential role of metabolic parameters as biomarkers to understand the pathophysiology. Indeed, lower hyperhomocysteinemia levels were observed in demyelinating patterns, highlighting a potentially biochemical difference between the groups: plasma homocysteine could also be used as a marker of neurological severity. The homocysteine assay used in these conditions must enable the patient to be managed rapidly: it would therefore be preferable to use rapid methods such as immunoanalysis. On the other hand, plasma methylmalonic acid did not differ between groups, which also suggests that other mechanisms have yet to be identified in the pathophysiology of N 2 O abuse.

Longitudinal follow‐up and prognostic factors in nitrous oxide‐induced neuropathy

Understanding Neuropathy Features in the Context of Nitrous Oxide Abuse: A Combined Electrophysiological and Metabolic Approach

Factors affecting the topography of nitrous oxide‐induced neurological complications

B-301 Deciphering Neuropathy features in the Context of Nitrous Oxide abuse: An Integrated Analysis of Electrophysiology and Metabolism

Marked increase in severe neurological disorders after nitrous oxide abuse: a retrospective study in the Greater Paris area

Multidisciplinary rehabilitation following recreational nitrous oxide (N2O) misuse: evaluating service provision and rehabilitation outcomes in a cohort with serious disability

Evaluation of an ambulatory care pathway for patients with nitrous oxide-induced myeloneuropathy

Nitrous oxide abuse direct measurement for diagnosis and follow-up: update on kinetics and impact on metabolic pathways

Cracking the Whippet: The Inconsistent Treatment of Myeloneuropathy Secondary to Chronic Nitrous Oxide Misuse

Case report: Recreational nitrous oxide abuse triggered peripheral neuropathy possibly through the immune-mediated pathogenesis

Brain and body disconnect: A retrospective case series of subacute combined degeneration of the spinal cord from chronic nitrous oxide use in Perth, Western Australia

Mechanisms and recent advances in the diagnosis and treatment of nitrous oxide-induced peripheral neuropathy: a narrative review

Using machine learning to identify factors related to nitrous oxide (laughing gas) relapse among adolescents.

The Neurological Pupil index for outcome prognostication in people with acute brain injury (ORANGE): a prospective, observational, multicentre cohort study

Nitrous Oxide Induced Subacute Combined Degeneration with Longitudinally Extensive Myelopathy with Inverted V-sign on Spinal MRI: a Case Report and Literature Review

Long-term survival of participants in a phase II randomized trial of RNS60 in amyotrophic lateral sclerosis

Neurocognitive functioning following lung cancer treatment: The PRO-Long Study

Long-term survival following initiation of home non-invasive ventilation: a European study

Acute Nitrous Oxide‐induced Neuropathy Mimicking Guillain‐Barré Syndrome

Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity

Nitrous oxide abuse in a 21-year-old female: a case report and review of literature